Solithromycin is a ketolide antibiotic, a semisynthetic derivative of erythromycin, primarily used to treat bacterial infections, particularly those caused by drug-resistant strains such as Streptococcus pneumoniae and Haemophilus influenzae. It is effective against community-acquired bacterial pneumonia (CABP) due to its ability to inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. The drug is also being studied for its potential in treating other respiratory infections, sexually transmitted infections like gonorrhea, and skin and skin structure infections. Its broad-spectrum activity, including against atypical pathogens, and favorable oral bioavailability make it a convenient option for outpatient treatment. Additionally, solithromycin shows promise in addressing infections where other antibiotics have failed, offering a valuable alternative in the fight against antibiotic resistance. As a research reagent, it is supplied as a white to off-white solid with high purity (≥99%).